There is currently no cure for spinal<unk><unk> .  There has been great interest in identifying agents that can increase the amount of full- length SMN protein by upregulating expression of the SMN2 gene. Many clinical trials are ongoing to find the most reliable<unk><unk> .
Several new<unk><unk>  have shown encouraging results and helped in designing future clinical trials. Some of them currently used in clinical trials are as follows –
Quantitative muscle ultrasound
The Six-Minute Walk Test (6MWT) – In case of ambulatory SMA patients.
10 minute walk/run test
The Hammersmith Motor Scale
The Hammersmith Functional Motor Scale Expanded (HFMSE)
Knee flexor strength test
The Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)
The Gross Motor Function<unk> ent
Motor unit number estimation (MUNE)
Compound motor action potential (CMAP) amplitude
Serologic biomarkers (SMN mRNA and protein levels)
Spinal muscular atrophy outcome measures
Spinal muscular atrophy epidemiology and demographics
Spinal muscular atrophy therapeutics development
Charcot-Marie-Tooth disease epidemiology and demographics
Noonan syndrome epidemiology and demographics
Leopard syndrome epidemiology and demographics
Adrenoleukodystrophy epidemiology and demographics
Wolff-Parkinson-White syndrome epidemiology and demographics